Nur fatmawati
16611047
Irinotecan in combination with new agents.
Intensification and combination with new agents,
including biological response modifiers. The combination of irinotecan with
capecitabine is feasible and has promising activity. Diarrhea and neutropenia
are dose limiting. Overall response rates (RRs) in the 40% to 60% range are
seen from preliminary data. Work in progress is assessing the combination of
irinotecan with UFT/leucovorin (LV). The use of irinotecan together with
raltitrexed is also being investigated, as is its combination with
oxaliplatin.Iirinotecan plus oxaliplatin in second-line patients report median
survivals of 11-12 months. It seems possible to safely escalate the dose of
single-agent irinotecan to 500 mg/m(2) in patients showing good tolerance of
the drug. Irinotecan can be used in combination with LV5FU2 at doses up to 260
mg/m(2), especially if only one bolus of 5-fluorouracil (5-FU) is given.
Control of tumor growth is achieved in 90% of patients. Preliminary data
suggest that regimens based on 5-FU/LV and irinotecan can safely be combined
with the anti-epidermal growth factor receptor (EGFR) antibody cetuximab.
Clinically, it can safely be administered with irinotecan, and studies in CRC
are planned.
No comments:
Post a Comment